摘要
目的:系统评价中成药相关治疗方案对比常规西药或安慰剂治疗对慢性心力衰竭(CHF)患者整体临床疗效及相关结局指标的影响。方法:检索8个数据库2014-2024年间中成药相关治疗方案对比常规西药或安慰剂治疗CHF患者的随机对照试验并采用Stata16.0软件进行Meta分析。结果:最终纳入35篇文献,结果显示,与常规西药或安慰剂治疗相比,采用中成药相关治疗方案可有效改善CHF患者整体临床疗效(RR=1.22;95%CI=1.18,1.26;P<0.0001)、LVEF(SMD=1.03;95%CI=0.82,1.25;P<0.0001)、LVESD(SMD=-0.70;95%CI=-0.86,-0.53;P<0.0001)、LVEDD(SMD=-0.77;95%CI=-0.97,-0.58;P<0.0001)、NT-proBNP(SMD=-0.57;95%CI=-0.69,-0.45;P<0.0001)以及不良反应发生率(RR=0.57;95%CI=0.35,0.94;P=0.028<0.05)。结论:中成药相关治疗方案可有效改善CHF患者整体临床疗效、心功能指标与不良反应发生率。
Objective:To systematically evaluate the impact of Chinese patent medicine related treatment regimens compared with conventional western medicine or placebo treatment on the overall clinical efficacy and related outcome indicators in patients with chronic heart failure(CHF).Methods:8 databases were searched for randomized controlled trials of Chinese patent medicine related treatment options compared with conventional western medicine or placebo in the treatment of CHF patients from 2014 to 2024,and Meta-analysis was performed using Stata16.0 software.Results:Finally,35 articles were included.The results showed that compared with conventional western medicine or placebo treatment,treatment options related to proprietary Chinese medicines can effectively improve the overall clinical efficacy of CHF patients.(RR=1.22;95%CI=1.18,1.26;PR<0.0001)、LVEF(SMD=1.03;95%CI=0.82,1.25;P<0.0001)、LVESD(SMD=-0.70;95%CI=-0.86,-0.53;P<0.001)LVEDD(SMD=-0.77:95%CI=-0.97,-0.58;P<0.0001),NT-proBNP(SMD=-0.57;95%CI=-0.69,-0.45;PR<0.0001)and the incidence of adverse reactions(RR=0.57;95%CI=0.35,0.94;P-0.028<0.05).Conclusion:Chinese patent medicine related treatment regimens can effectively improve the overall clinical efficacy,cardiac function indicators and the incidence of adverse reactions in patients with CHF.
作者
徐昊杨
杜建军
刘晓旭
马奎影
乌日罕
赵明
XU Haoyang;DU Jianjun;LIU Xiaoxu;MA Kuiying;WU Rihan;ZHAO Ming(Inner Mongolia Minzu University,Tongliao,Inner Mongolia 028000;Tongliao People's Hospital,Tongliao,Inner Mongolia 028000;Affiliated Hospital of Inner Mongolia Minzu University,Tongliao,Inner Mongolia 028000;Inner Mongolia Autonomous Regional Radio and Television Administration,Hohhot,Inner Mongolia O10050)
出处
《内蒙古中医药》
2024年第11期164-168,共5页
Inner Mongolia Journal of Traditional Chinese Medicine
基金
蒙药苏格木勒-3汤对脓毒血症诱发房颤的作用及机制研究(2023LHMS08082)
网腔钙结合蛋白在房颤发病过程中的作用(2017MS(LH)0824)。
关键词
慢性心力衰竭
中成药
META分析
Chronic heart failure
Chinese patent medicine
Meta analysis
